drugset / Trial / NCT05421078

A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

NCT05421078

Phase 2 Completed 102 enrolled NewAmsterdam Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study in Japanese patients to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy.

Timeline

Start
2022-06-27
Primary completion
2023-03-24
Completion
2023-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Obicetrapib Small molecule 2.5 mg
Subject Obicetrapib Small molecule 5 mg
Subject Obicetrapib Small molecule 10 mg

Indications